Ardelyx, Inc, a specialized biopharmaceutical company, develops and sells medicines for the treatment of cardio renal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone510-745-1700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.61 million
Profitability
Miscellaneous
Employees86
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Ardelyx (NASDAQ:ARDX) Frequently Asked Questions
What is Ardelyx's stock symbol?
Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."
How were Ardelyx's earnings last quarter?
Ardelyx Inc (NASDAQ:ARDX) issued its quarterly earnings data on Friday, August, 9th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.02. The biopharmaceutical company earned $0.02 million during the quarter, compared to the consensus estimate of $0.60 million. View Ardelyx's Earnings History.
When is Ardelyx's next earnings date?
What price target have analysts set for ARDX?
3 analysts have issued 12 month price targets for Ardelyx's stock. Their forecasts range from $9.00 to $15.00. On average, they anticipate Ardelyx's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 121.8% from the stock's current price. View Analyst Price Targets for Ardelyx.
What is the consensus analysts' recommendation for Ardelyx?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ardelyx.
Has Ardelyx been receiving favorable news coverage?
News coverage about ARDX stock has trended neutral this week, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Ardelyx earned a daily sentiment score of 0.2 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Ardelyx.
Are investors shorting Ardelyx?
Ardelyx saw a increase in short interest in September. As of September 30th, there was short interest totalling 1,420,000 shares, an increase of 45.3% from the August 30th total of 977,600 shares. Based on an average daily trading volume, of 1,050,000 shares, the days-to-cover ratio is presently 1.4 days. Currently, 3.1% of the company's stock are sold short. View Ardelyx's Current Options Chain.
Who are some of Ardelyx's key competitors?
Some companies that are related to Ardelyx include Radius Health (RDUS), Enanta Pharmaceuticals (ENTA), Zymeworks (ZYME), BELLUS Health (BLUSF), Turning Point Therapeutics (TPTX), ArQule (ARQL), Gossamer Bio (GOSS), Innoviva (INVA), Dicerna Pharmaceuticals (DRNA), Esperion Therapeutics (ESPR), Endo International (ENDP), AnaptysBio (ANAB), Epizyme (EPZM), Theravance Biopharma (TBPH) and Y-mAbs Therapeutics (YMAB).
What other stocks do shareholders of Ardelyx own?
Who are Ardelyx's key executives?
Ardelyx's management team includes the folowing people:
- Mr. Michael G. Raab, Pres, CEO & Director (Age 54)
- Mr. David Rosenbaum, Chief Devel. Officer (Age 58)
- Mr. Mark E. Kaufmann, CFO & Treasurer (Age 51)
- Mr. Jeffrey W. Jacobs, Sr. VP of Technical Operations (Age 56)
- Mr. Bryan Shaw, Chief Accounting Officer, VP and Controller (Age 65)
Who are Ardelyx's major shareholders?
Ardelyx's stock is owned by many different of retail and institutional investors. Top institutional investors include Rhumbline Advisers (0.12%) and Wedbush Securities Inc. (0.05%). Company insiders that own Ardelyx stock include David P Rosenbaum, Elizabeth A Grammer, Gordon Ringold, Mark Kaufmann, Michael Raab, Reginald Seeto and Scott D Sandell. View Institutional Ownership Trends for Ardelyx.
Which institutional investors are selling Ardelyx stock?
ARDX stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have sold Ardelyx company stock in the last year include David P Rosenbaum, Elizabeth A Grammer, Mark Kaufmann, Michael Raab and Scott D Sandell. View Insider Buying and Selling for Ardelyx.
Which institutional investors are buying Ardelyx stock?
How do I buy shares of Ardelyx?
Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Ardelyx's stock price today?
One share of ARDX stock can currently be purchased for approximately $4.96.
How big of a company is Ardelyx?
Ardelyx has a market capitalization of $311.49 million and generates $2.61 million in revenue each year. The biopharmaceutical company earns $-91,300,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Ardelyx employs 86 workers across the globe.View Additional Information About Ardelyx.
What is Ardelyx's official website?
How can I contact Ardelyx?
Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]
MarketBeat Community Rating for Ardelyx (NASDAQ ARDX)
MarketBeat's community ratings are surveys of what our community members think about Ardelyx and other stocks. Vote "Outperform" if you believe ARDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
